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Abstract 
In 2006, the Hospital Infection Society was funded by the respective health services 
in England, Wales, Northern Ireland and the Republic of Ireland to conduct a 
prevalence survey of healthcare-associated infection (HCAI).  Here, we report the 
prevalence of pneumonia and lower respiratory tract infection other than pneumonia 
(LRTIOP) in these four countries.  The prevalence of all HCAIs was 7.59% (5,743 / 
75,694). Nine hundred (15.7%) of these infections were pneumonia, and 402 (7.0%) 
were LRTIOP. The prevalence of both infections was higher for males than for 
females, and increased threefold from the under 35s to the over 85s (p<0.001). At the 
time of the survey or in the preceding seven days, 23.7% and 18.2% of patients with 
pneumonia and LRTIOP, respectively, were mechanically ventilated compared to 
5.2% of patients in the whole study population. Meticillin-resistant Staphylococcus 
aureus (MRSA) was the cause of pneumonia and LRTIOP in 7.6% and 18.1% of 
patients, respectively (p<0.001).  More patients with LRTIOP (4.2%) had concurrent 
diarrhoea due to Clostridium difficile compared to patients with pneumonia (2.4%), 
but this failed to reached statistical significance (p=0.08). Other healthcare-associated 
infections were present in 137 (15.2%) of patients with pneumonia and 66 (16.4%) of 
those with LRTIOP. The results suggest that reducing instrumentation, such as 
mechanical ventilation where possible, should help reduce infection.  The higher 
prevalence of MRSA as a cause of LRTIOP suggests a lack of specificity in 
identifying the microbial cause and the association with Clostridium difficile 
emphasises the need for better use of antibiotics. 
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Introduction 
Prevalence surveys of healthcare-associated infection (HCAI) are conducted in many 
countries to determine the proportion of patients that have an infection, and to identify 
those areas that require prioritisation for prevention and control. In Finland, a national 
prevalence survey carried out in 2005 and involving 30 hospitals found an overall 
prevalence of HCAI of 8.5%.1   In the UK and Ireland, over 75,000 patients were 
surveyed in 2006 in one of the largest surveys of its kind.  The overall prevalence of 
HCAI was 7.59%.2,3   The most common HCAI involved the gastro-intestinal tract but 
pneumonia was the third most common infection recorded.2    
 
Although pneumonia and other lower respiratory tract infections are particularly 
prevalent in patients in intensive care units (ICUs) because of the strong association 
with mechanical ventilation, lower respiratory tract infections account for a 
substantial proportion of the overall burden of HCAI.4  Extrinsic risk factors for lower 
respiratory tract infection include endotracheal intubation, mechanical ventilation and 
micro-aspiration of the oropharynx and intrinsic factors which relate to the individual 
patient include their underlying disease, the presence of immunosupression, etc.4   
 
Here, we outline the results from the Hospital Infection Society (HIS) Prevalence 
survey of HCAI as they relate to pneumonia and lower respiratory tract infection 
other than pneumonia (LRTIOP), conducted in the UK (excluding Scotland which 
used different methodologies) and the Republic of Ireland in 2006, and discuss how 
the results might indicate the priorities for future preventative strategies.   
 
 
Deleted: i
HIS06-RTI(9) 240609 Page  4  of  16 
Materials and Methods 
All publicly funded acute hospitals with adult in-patients were eligible to participate 
in the HIS study in 2006.  Paediatric hospitals, mental health trusts, military hospitals, 
non-acute hospitals and private hospitals were excluded, except in the Republic of 
Ireland where some private hospitals participated.  
 
The Centre for Disease Control (CDC) and Prevention definition of HCAI was used, 
i.e. a localised or systemic condition resulting from an adverse reaction to the 
presence of an infectious agent or reagent or its toxins and that was not present or 
incubating at the time of admission to the participating hospital.  It also had to meet 
the CDC criteria for specific infections, which are widely used for surveillance 
purposes.5    
 
The data were collected between mid-February and the end of May 2006 using 
standardised data forms. Data were collected for all active healthcare associated 
system infections recording whether the infection was device- or procedure-related, if 
MRSA was the causative organism and whether the patient developed a secondary 
bloodstream infection. Additional information was requested for primary bloodstream 
infection, pneumonia, surgical site infection and urinary tract infection. For 
pneumonia, the infection was categorised as either clinically defined pneumonia, 
pneumonia with specific laboratory findings, or pneumonia in immunocompromised 
patients, with algorithms provided to guide the categorisation. LRTIOP includes 
bronchitis, tracheobronchitis, bronchiolitis, tracheitis, without evidence of 
paneumonia and lung abscess and empyema.5 The relationship between risk factors or 
any variables associated with infection are summarised by odds ratios with 95% 
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confidence intervals calcuated by the score method.6 For the variation between age 
groups, one degree of freedom for linear trend is reported.   
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Results 
The overall prevalence of HCAI was 7.59% (5,743/75,694).  Full details of the overall 
results and risk factors for all HCAIs can be found elsewhere.2,3  Nine hundred 
(15.7%) of these infections were classed as pneumonias, of which 719 (79.9%) were 
clinically defined pneumonia;165 (18.3%) were ventilator-associated pneumonia 
(VAP); 121 (13.4%) were pneumonia with specific laboratory findings and 30 (3.3%) 
were in immunocompromised patients. Of all HCAI 402 (7.0%) of the infections were 
classed as LRTIOP. The prevalence of both infections increased substantially with 
age, threefold from the under 35s to the over 85s (Table 1; p<0.001) and was higher 
for males than for females, especially for pneumonia (1.53% vs. 0.92%, p<0.001), but 
also for LRTIOP (0.62% vs 0.46%, p=0.003).  
 
Mechanical ventilation was used either currently or in the preceding seven days in 
23.7% of patients with pneumonia and in 18.2% of patients with LRTIOP, compared 
to 5.2% of patients in the whole study population (Table 2). The increased risk related 
much more strongly to current than recent use.  
 
 
 
Meticillin-resistant Staphylococcus aureus (MRSA) was the cause in 18.1% of 
LRTIOPs compared to 7.6% of pneumonias, p<0.001 (Table 3).  These figures 
exclude 47 and 16 patients with pneumonia and LRTIOP respectively where the 
question was either not answered or where susceptibility testing results were not 
available. Rather more patients with LRTIOP (4.2%) had concurrent diarrhoea due to 
Clostridium difficile, compared to patients with pneumonia (2.4%), p=0.08. There 
were other concomitant infections such as surgical site infection, primary bloodstream 
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infection etc. in 137 (15.2%) of the patients with pneumonia and 66 (16.4%) of 
patients with LRTIOP.  
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Discussion 
This survey, has confirmed the burden of lower respiratory tract infection in patients 
with healthcare-associated infection.  The limitations of the data reported here include 
the narrow dataset used;  however the focussed dataset was designed to facilitate the 
participation of as large a number of centres and the inclusion of as many patients as 
possible, hence the success in recruiting over 75,000 patients.  The absence of any 
data relating to intrinsic risk factors, (apart from age and sex), such as medications, 
underlying lung disease, other chronic illnesses, etc, means that it is difficult to 
identify clearly from this survey, all those categories of patients at greatest risk.  
Other limitations include the seasonal implications of conducting a prevalence study 
over a relatively prolonged period of time i.e. February to May 2006.  Some 
variations in the data collection between the various health systems in England, 
Wales, Northern Ireland and the Republic of Ireland may have occurred but all used 
the same data set and unmodified CDC definitions.   
 
The CDC definitions have been widely employed for surveillance purposes.5 
Following this prevalence survey an evaluation was carried out in England and 
Northern Ireland and participants found the pneumonia definitions the most difficult 
to apply of all the definitions. In particular a number of hospitals commented that the 
requirement for at least one chest x-ray to complete the pneumonia diagnosis meant 
that some infections,  judged clinically to be pneumonia, could not be categorised as 
such because x-rays are not necessarily routinely obtained in the management of such 
patients. In Wales the prevalence of pneumonia was lower (0.68%) than in the other 
countries (0.86-1.29%)2, and this was also thought to be due to the difficulty in 
accessing chest x-ray results to complete the diagnosis in some hospitals.7  
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Much of the data on pneumonia published elsewhere focusses on the ventilated 
patient in the intensive care unit, where S. aureus is a common and important cause,8-
11
 but there is relatively little data on patients outside critical care units.  In our study, 
MRSA was more common in LRTIOP, not commonly described in ventilated patients 
compared with pneumonia, and as LRTIOP includes empyema, it is often a more 
prolonged illness and this impacts on prevalence. 
 
   
In recent UK guidelines on the management of hospital-acquired pneumonia, 
avoidance of endotracheal aspirations, and quantifying the number of pathogens on 
culture with the presence of intracellular pathogens as predictors of infection were the 
only guidelines with a strong evidence base.12  A recent Cochrane review found no 
evidence that the use of quantitative cultures of respiratory secretions results in 
reduced mortality, reduced periods of ventilation or better antibiotic use, compared 
with non-quantitative cultures.13  
 
Measures to prevent VAP are well described although the evidence-base is sub-
optimal.  The use of sucralfate as stress ulcer prophylaxis, the use of oscillating beds, 
and selective digestive tract decontamination have a scientific base.16   Developing 
care protocols for weaning and sedation, sucralfate for stress ulcer prophylaxis, 
physiotherapy, respiratory therapists and keeping patients in the semi-recumbent 
position (30-45oC), had the strongest evidence base in recent UK guidelines.12 
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A  higher proportion of infections were recorded as being due to MRSA in patients 
with LRTIOP (18.1%) compared with pneumonia (7.6%), and C. difficile was also 
more common in the LRTIOP group.  This may suggest poor specificity in the 
diagnosis of LRTIOP, i.e. MRSA from respiratory samples representing colonisation 
only and not true infection.  The consequent overuse of antibiotics to treat patients 
with suspected LRTIOP contributes to C. difficile, being more common than in 
patients with pneumonia. 
 
There is increasing attention on quality measures of health delivery as they pertain to 
HCAI, and VAP rates have been suggested as one such measure.15  However, 
Klompas and Platt have recently argued against VAP as a quality measure for 
benchmarking and for public reporting, as the clinical, laboratory and radiological 
diagnosis is inaccurate and the CDC definitions were developed for epidemiological 
surveillance, but not necessarily for inter-institutional comparisons.16   Nonetheless, 
the 2006 HIS Prevalence Survey  has confirmed the important contribution that lower 
respiratory tract infections make to the overall prevalence of HCAI.  
 
Standard infection prevetion and control precautions together with other measures, 
e.g. avoiding mechanical ventilation or reducing its duration where possible, 
sucralfate for stress ulcer prophylaxis, and the management of patients in the semi-
recumbent position, are all measures that will contribute to reducing its prevalence.  
Other interventions such as the more accurate diagnosis of LRTIOP and improved 
antibiotic stewardship will contribute to reducing MRSA and C. difficile.  
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In a prospective study in Spain, the incidence of hospital-acquired pneumonia was three 
cases/1,000 hospital admissions and an aetiological agent was obtained in 36.4% of 
cases.8 When comparing the outcomes from two different treatments in 544 patients with 
VAP, S. aureus was the most commonly identified pathogen, recovered in 221 patients, 
including 91 with MRSA.9  In a retrospective analysis of pooled patient data from 
multiple clinical trials in France, patients with MRSA VAP were significantly older than 
those with meticillin-susceptible S. aureuswho had a median duration of mechanical 
ventilation of eight days, compared with 13 days for patients with MRSA.10   In a study 
by Shorr and colleagues, patients with MRSA had a longer stay in the ICU and their 
treatment was associated with considerable higher costs (US $7,731) per patient.11   
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There is increasing attention on quality measures of health delivery as they pertain to 
HCAI, and VAP rates have been suggested as one such measure.12  However, Klompas 
and Platt have recently argued against VAP as a quality measure for benchmarking and 
for public reporting, as the clinical, laboratory and radiological diagnosis is inaccurate 
and the CDC definitions were developed for epidemiological surveillance, but not 
necessarily for inter-institutional comparisons.13 
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, and the same applies irrespective of whether invasive or non-invasive sampling is 
carried out. 
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Therefore although there is confusion about the approach to the accurate diagnosis of 
pneumonia, esepcially in ventilated patients, the CDC definitions are used internationally 
for surveillance purposes whatever their shortcomings in the management of the 
individual patient.  
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, even if there is concern about the emergence of antibiotic resistance with this approach 
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Standard precautions including hand hygiene and good professional practice are also 
essential.  Clearly, avoiding instrumentation, e.g. intubation or tracheostomy, where 
clinically possible and reducing as much as possible the duration of ventilation, will also 
contribute to reducing VAP rates.  
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the use of but not the routine changing of heat moisture exchangers, non-invasive 
ventilation where possible,  
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Although antibiotic-associated diarrhoea due to C. difficile was first described in 1978, 
the emergence of new strains, particularly ribotype 027 which is associated with 
increased transmissibility and virulence, has focusssed greater efforts on prevention and 
control.17   The association between C. difficile ribotype 027 and the use of 
fluoroquinolones has led to the banning of all such agents in some hospitals together with 
limitations on the use of cephalosporins and clindamcyin.18 
 
 
